The Governing Council of the University of Toronto

Regeneron's pozelimab and cemdisiran (poze-cemdi) in PNH showed 96% LDH control vs 80% with ravulizumab, 93% LDH normalization vs 65% with ravulizumab, and 84% LDH decrease at week 26. Safety profile similar to ravulizumab, with 84% TEAEs vs 87% for ravulizumab. Subcutaneous delivery every 4 weeks with potential for self-administration.

Phase 3 trial data shows poze-cemdi combination treatment outperforms ravulizumab in controlling PNH, with better LDH level management. Poze-cemdi, a first-in-class treatment combining an antibody and siRNA targeting C5, offers potential for self-administration and improved patient outcomes.

Phase 3 trial data showed the poze-cemdi combination treatment outperformed standard ravulizumab in controlling PNH, with 96% achieving LDH control vs. 80% on ravulizumab. Poze-cemdi offers potential for self-administration, marking a significant advancement in PNH treatment.

Phase 3 trial data showed the poze-cemdi combination treatment outperformed standard ravulizumab in controlling PNH disease, measured by LDH levels. Poze-cemdi achieved higher LDH control and normalization rates, with a safety profile consistent with approved C5 inhibitors. A registrational cohort is ongoing to further evaluate poze-cemdi against eculizumab.

Phase 3 trial data showed the poze-cemdi combination treatment outperformed standard ravulizumab in controlling PNH, with 96% achieving LDH control vs. 80% on ravulizumab. A registrational cohort is ongoing, comparing poze-cemdi to eculizumab. Poze-cemdi offers potential for self-administration with infrequent dosing.

Phase 3 trial data shows poze-cemdi, a first-in-class combination treatment, outperforms standard ravulizumab in controlling PNH disease, measured by LDH levels. Poze-cemdi achieved higher LDH control and normalization rates, with a safety profile consistent with approved C5 inhibitors. Ongoing studies aim to confirm these findings.

Phase 3 trial data showed the poze-cemdi combination treatment outperformed standard ravulizumab in controlling PNH, with better LDH levels. A registrational cohort is ongoing, comparing poze-cemdi to eculizumab. Poze-cemdi offers potential for self-administration and improved disease control.

Phase 3 trial data showed the poze-cemdi combination treatment achieved better disease control in PNH patients, measured by LDH levels, compared to standard ravulizumab. Poze-cemdi, combining an antibody and siRNA targeting C5, demonstrated superior LDH control and normalization, with potential for self-administration, indicating a promising treatment approach for PNH and other complement-mediated diseases.

Phase 3 trial data showed poze-cemdi combo treatment improved LDH control in PNH patients compared to ravulizumab, with 96% achieving adequate LDH control and 93% achieving normalization. A registrational cohort is ongoing, comparing poze-cemdi against eculizumab.

A clinical trial combining chemotherapy with blinatumomab for B-cell acute lymphoblastic leukemia (B-ALL) in children showed a 61% reduction in relapse risk, significantly improving disease-free survival rates, marking a new standard of care in childhood cancer treatment.